Diabetes drug shows promise for stubborn fluid in heart and kidney patients
NCT ID NCT05305495
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study looked at whether adding empagliflozin (a diabetes drug) to standard water pills helps people with acute heart failure and moderate-to-severe kidney disease urinate out more excess fluid. 25 adults participated, and researchers measured urine output over three hours. The goal was to see if the combination works better than the water pill alone for those who don't respond well to usual treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Institute of the McGill University Health Center
Montreal, Quebec, Canada
Conditions
Explore the condition pages connected to this study.